Biomarker discovery randomized phase IIb trial with carboplatin-cyclophosphamide versus Paclitaxel with or without atezolizumab as first-line treatment in advanced triple negative Breast cancer (Triple-B study)

Trial Profile

Biomarker discovery randomized phase IIb trial with carboplatin-cyclophosphamide versus Paclitaxel with or without atezolizumab as first-line treatment in advanced triple negative Breast cancer (Triple-B study)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Carboplatin; Cyclophosphamide; Paclitaxel
  • Indications Breast cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms Triple-B
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 28 Apr 2017 Atezolizumab has been added to the study.
    • 22 Jul 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top